Rapid STI Testing Market

The Global Rapid STI Testing Market size was estimated at USD 1.5 billion in 2025 and is projected to reach approximately USD 3.45 billion by 2035, growing at a CAGR of 8.7% from 2026 to 2035. Rapid testing is becoming strategically important to sexual healthcare delivery as providers prioritize timely diagnosis, decentralized access, confidential screening, and treatment decisions during a single patient encounter.

Key Highlights

• North America held the largest regional revenue share in 2025, supported by established diagnostic infrastructure, regulatory pathways, and growing availability of point-of-care and home-testing products.
• Molecular diagnostics/NAAT represented the dominant technology segment, reflecting demand for high analytical sensitivity and pathogen-specific detection.
• Home-Based Self-Testing is positioned as the fastest-growing testing-setting segment, supported by privacy, convenience, and expanding consumer access to authorized diagnostic products.
• Multiplex testing and compact molecular platforms are reshaping the technology landscape by consolidating pathogen detection and shortening time to clinical decisions.
• Rising STI screening requirements, asymptomatic infection detection, and public health programs are strengthening institutional procurement and recurring consumables demand.
• Commercial differentiation is shifting toward complete test-to-care solutions that combine specimen collection, rapid results, clinical interpretation, and referral or treatment pathways.

Rapid STI Testing Market Overview

Rapid STI testing occupies an increasingly important position between conventional centralized laboratory diagnostics and immediate clinical decision-making. The category covers diagnostic products that provide timely results for sexually transmitted infections through molecular amplification, immunoassay, or other rapid detection methods. Its commercial scope includes professional point-of-care systems, decentralized clinical testing, and self-testing products designed for use outside conventional healthcare facilities. Buyers assess these solutions through diagnostic performance, time to result, specimen compatibility, workflow requirements, regulatory status, and total cost per reportable result.

Procurement behavior differs across healthcare systems. Hospitals and diagnostic laboratories prioritize validated performance, throughput, quality assurance, and integration with existing laboratory infrastructure. Sexual health clinics and community organizations emphasize accessibility, staff usability, and same-visit clinical decisions. Retail healthcare providers and consumers place greater weight on convenience, privacy, clear instructions, and accessible follow-up services. These differences create distinct purchasing requirements rather than a single standardized product market.

Deployment maturity also varies by pathogen and technology. Rapid HIV and syphilis testing has established clinical and public health applications, while rapid molecular testing for chlamydia, gonorrhea, and other bacterial infections is expanding the addressable product landscape. The World Health Organization’s diagnostic guidance covers laboratory and point-of-care approaches, specimen handling, and quality management, reinforcing the importance of reliable testing pathways across different resource settings.

Key Market Drivers & Industrial Demand Dynamics

The global burden of sexually transmitted infections is a foundational demand driver because delayed diagnosis sustains transmission and increases the risk of complications. Many infections present without clear symptoms, making symptom-led diagnosis insufficient for effective screening programs. Rapid tests strengthen screening access by reducing the time between specimen collection and diagnostic information, particularly in clinics serving populations with limited access to centralized laboratories. For healthcare providers, shorter turnaround supports faster treatment decisions, partner services, and improved continuity of care. For public health agencies, accessible testing supports outreach programs and earlier identification of infections in underserved communities. These operational benefits position rapid diagnostics as a practical component of broader STI control strategies, while manufacturers gain recurring demand for test kits, reagents, collection materials, and platform-specific consumables.

The shift toward decentralized healthcare delivery is another major commercial driver. Conventional laboratory workflows require specimen transport, processing capacity, result communication, and patient follow-up. These steps introduce delays and increase the risk that individuals do not return for treatment. Point-of-care molecular systems and rapid immunoassays move testing closer to the patient, supporting same-visit clinical decisions in urgent care facilities, sexual health clinics, community health centers, and selected retail settings. Healthcare purchasers evaluate decentralized products according to instrument footprint, operator training, power requirements, storage conditions, quality controls, and test cost. Vendors that reduce workflow complexity while preserving diagnostic reliability gain a stronger position in facilities with limited laboratory infrastructure. This transition also expands demand beyond major hospitals into smaller clinics and community-based testing networks.

Consumer preference for confidential and convenient sexual healthcare is accelerating interest in home-based testing. Stigma, appointment barriers, travel requirements, and concerns about privacy influence whether individuals seek screening. Self-collection and home-testing formats address several of these obstacles by allowing users to collect specimens or conduct tests in private settings. Regulatory authorization for at-home chlamydia, gonorrhea, and trichomoniasis testing in the United States represents an important commercial development. Visby Medical received FDA De Novo authorization for its Women’s Sexual Health Test in March 2025, establishing a new route for over-the-counter molecular STI testing. Its subsequent national launch broadened consumer access through direct-to-consumer distribution and delivery partners. The commercial opportunity extends beyond the test itself to digital result delivery, telehealth consultation, confirmatory testing, and treatment coordination.

Technology advancement is improving the commercial proposition of rapid STI diagnostics. Molecular methods, particularly nucleic acid amplification testing, provide pathogen-specific detection and support multiplex panels that identify more than one infection from a specimen. Compact instruments, closed cartridges, simplified preparation, and automated result interpretation reduce the operational burden on frontline staff. Rapid immunoassays remain relevant where affordability, ease of use, and minimal equipment requirements take priority, especially in screening programs and resource-constrained environments. Manufacturers are therefore competing across different performance and cost requirements rather than through one universal technology model. The ability to balance sensitivity, specificity, time to result, specimen flexibility, and per-test economics determines suitability across clinical settings. These technology improvements strengthen demand for differentiated product portfolios and integrated diagnostic workflows.

Government screening programs and institutional healthcare procurement provide an additional source of recurring demand. Public health organizations require scalable testing approaches for STI prevention, antenatal screening, community outreach, and targeted services for populations facing barriers to conventional healthcare. Procurement decisions consider product authorization, supply continuity, price, shelf life, training, local distribution, and compatibility with national testing algorithms. International guidance also influences product selection by emphasizing quality-assured testing and appropriate diagnostic pathways. In India, updated national STI and reproductive tract infection guidance incorporates laboratory diagnosis, nucleic acid amplification testing, point-of-care testing, and rapid diagnostic approaches within a broader care framework. Such policies support structured demand from public facilities and implementing organizations, while creating opportunities for manufacturers able to meet tender requirements and local service needs.

Segmentation Analysis

Rapid STI Testing Market, By Technology

Technology segmentation distinguishes the diagnostic principle used to identify infection. Molecular Diagnostics/NAAT includes PCR and other nucleic acid amplification approaches, while Rapid Immunoassays cover antigen or antibody detection formats, including lateral-flow and related rapid platforms. Buyers select technology according to pathogen characteristics, clinical purpose, sensitivity requirements, equipment availability, result time, and total cost per test. Molecular diagnostics/NAAT represents the largest segment because it supports direct pathogen detection and multiplex testing for infections such as chlamydia and gonorrhea. Rapid Immunoassays remain commercially relevant for accessible screening, particularly where compact, low-complexity testing is prioritized. Molecular Diagnostics/NAAT is also positioned as the fastest-growing technology segment, supported by compact platforms, closed-cartridge workflows, and expanded near-patient applications.

Rapid STI Testing Market, By Infection Type

Infection type classifies tests according to the pathogen or infection targeted: Chlamydia, Gonorrhea, Syphilis, HIV, Trichomoniasis, Genital Herpes, Mycoplasma genitalium, and Other Sexually Transmitted Infections. This dimension reflects clinical screening protocols, prevalence patterns, patient risk profiles, and the availability of validated diagnostic products. Chlamydia and Gonorrhea collectively represent a leading commercial category because of their screening requirements, asymptomatic presentation, and demand for molecular confirmation. HIV and Syphilis remain established rapid-testing categories with public health and antenatal applications. Mycoplasma genitalium testing is an emerging area as clinical attention to persistent and recurrent infections strengthens demand for pathogen-specific diagnosis. Multiplex coverage for Chlamydia, Gonorrhea, and Trichomoniasis is a fast-growing product direction, while Mycoplasma genitalium represents an expanding specialized testing opportunity.

Rapid STI Testing Market, By Test Format

Test format separates Single-Pathogen Tests from Multiplex Tests according to the number of infections assessed within an individual test or assay panel. Single-Pathogen Tests suit targeted screening, follow-up testing, and programs built around a defined diagnostic requirement. Multiplex Tests consolidate detection of multiple pathogens, reduce repeated specimen collection, and support more efficient clinical workflows when symptoms overlap or co-infection is a concern. Single-Pathogen Tests maintain a substantial installed base because of established HIV and syphilis screening programs and focused clinical applications. Multiplex Tests are the fastest-growing segment as healthcare providers seek broader diagnostic information from a single encounter. Their commercial value depends on panel relevance, clinical validation, reagent economics, and the ability to avoid unnecessary testing.

Rapid STI Testing Market, By Sample Type

Sample type segmentation includes Blood, Urine, Genital Swabs, Oral and Rectal Swabs, and Other Specimen Types. Specimen selection depends on pathogen biology, anatomical exposure, test validation, patient preference, and collection infrastructure. Blood remains a major specimen category for HIV and syphilis screening, supported by established finger-prick and venous collection workflows. Genital swabs and urine are central to chlamydia and gonorrhea testing, with swab-based self-collection supporting home-based formats. Urine-based testing is commercially attractive for ease of collection and integration into clinical workflows. Genital Swabs are positioned for strong expansion as self-collection and home testing gain wider availability. Oral and Rectal Swabs serve specialized screening needs and broaden testing coverage for populations requiring site-specific diagnosis.

Rapid STI Testing Market, By Testing Setting

Testing Setting distinguishes Point-of-Care Testing, Home-Based Self-Testing, Decentralized Clinical Testing, and Laboratory-Based Rapid Testing. Point-of-Care Testing is conducted near the patient during a clinical encounter, while Home-Based Self-Testing is designed for consumer use without a conventional in-person testing appointment. Decentralized Clinical Testing covers testing performed at local healthcare sites outside centralized laboratory workflows, and Laboratory-Based Rapid Testing includes rapid-result procedures within diagnostic laboratory operations. Point-of-Care Testing represents the largest segment through established clinic, hospital, and public health applications. Home-Based Self-Testing is the fastest-growing segment, supported by regulatory progress, privacy preferences, direct-to-consumer access, and digital care pathways. Buyers compare usability, result delivery, referral arrangements, and test performance across these settings.

Rapid STI Testing Market, By End User

End-user segmentation includes Hospitals, Specialty Clinics, Diagnostic Laboratories, Public Health and Community Organizations, Pharmacies and Retail Healthcare Providers, and Home Users. Hospitals purchase rapid tests to support emergency, inpatient, outpatient, and antenatal diagnostic pathways. Specialty Clinics focus on sexual health screening, targeted diagnosis, and follow-up services, while diagnostic laboratories use rapid platforms to extend service offerings and reduce turnaround time. Hospitals and Specialty Clinics collectively represent the leading institutional demand base because of established testing workflows and recurring clinical requirements. Home Users constitute the fastest-growing end-user segment as authorized self-testing products and consumer distribution channels expand. Public Health and Community Organizations remain important purchasers for outreach and screening programs, while pharmacies and retail providers provide additional access points for decentralized testing.

Rapid STI Testing Market, By Distribution Channel

Distribution Channel comprises Direct Sales, Distributors and Medical Suppliers, Online Channels, and Government and Institutional Procurement. Direct Sales supports strategic hospital, laboratory, and clinic accounts requiring technical support, training, and negotiated supply arrangements. Distributors and Medical Suppliers provide geographic reach, inventory management, and access to fragmented healthcare facilities. Online Channels serve consumer testing and smaller purchasers, while Government and Institutional Procurement covers tenders, public health contracts, and bulk purchasing programs. Distributors and Medical Suppliers represent the largest channel because healthcare diagnostics depend on established supply networks and local service capabilities. Online Channels are the fastest-growing channel, driven by home testing, direct-to-consumer healthcare, and digital ordering. Government procurement remains strategically important where national programs prioritize standardized testing access and cost control.

Strategic Market Snapshot

The commercial structure of rapid STI diagnostics is moving from isolated test-kit sales toward integrated testing pathways. Product differentiation increasingly depends on the combined performance of assay chemistry, specimen collection, instrument design, result communication, and access to follow-up care. Molecular manufacturers compete on diagnostic accuracy, multiplex coverage, and turnaround time, while rapid immunoassay suppliers compete through affordability, ease of use, and deployment flexibility. Buyers evaluate total workflow economics rather than purchase price alone, including training, quality control, wastage, maintenance, and the cost of missed follow-up.

Home-based testing introduces a different commercial model built around consumer acquisition, digital engagement, privacy, and clinical referral. Institutional buyers continue to value validated performance and dependable supply, while public health purchasers emphasize affordability and equitable access. Over the forecast period, competitive advantage will favor suppliers that align product design with the operational needs of specific care settings and support a complete pathway from screening to treatment.

Value Chain, Cost Structure & Procurement Intelligence

The value chain begins with assay development, reagent sourcing, specimen collection components, cartridge or strip manufacturing, device assembly, quality control, regulatory authorization, and distribution. Molecular platforms carry costs associated with enzymes, primers, probes, cartridges, instrument development, and manufacturing validation. Immunoassay products generally emphasize membranes, antibodies, conjugates, buffers, packaging, and high-volume production efficiency. Deployment costs also include instruments, calibration, controls, staff training, information-system integration, and service support. For home tests, packaging, shipping, customer support, digital result delivery, and referral arrangements influence total economics.

Vendor pricing varies according to technology, panel breadth, test volume, instrument requirements, and contract structure. Hospitals and laboratories negotiate through annual supply agreements, reagent commitments, and platform placement arrangements. Public-sector buyers use tenders and framework contracts, while consumer products rely on retail or direct pricing. Procurement cycles are shaped by clinical validation, regulatory review, budget approval, and supply assurance. Vendors that demonstrate predictable consumable availability, low workflow complexity, and competitive cost per completed test strengthen procurement retention and operating efficiency.

Market Restraints & Regulatory Challenges

Regulatory compliance remains a central barrier because rapid STI tests require evidence supporting analytical performance, clinical validity, labeling, specimen claims, and intended-use populations. Requirements differ across jurisdictions and between professional-use and consumer-use products. Manufacturers face additional complexity when expanding indications, changing specimen types, or introducing multiplex panels. Data privacy is increasingly important for home testing and digital result delivery, where sensitive sexual health information requires secure handling, informed consent, and appropriate access controls.

Interoperability also affects deployment. Rapid platforms that cannot connect efficiently with laboratory information systems, electronic health records, or public health reporting workflows create additional administrative work. Clinical resistance arises when providers question test performance, lack training, or cannot ensure confirmatory testing and treatment follow-up. False results, inappropriate interpretation, supply interruptions, and inadequate referral pathways create enterprise risk. These constraints favor vendors with strong clinical evidence, transparent labeling, quality systems, and clear integration support.

Market Opportunities & Outlook 2026–2035

The forecast period creates opportunities for rapid molecular platforms, broader multiplex panels, and consumer-oriented testing pathways. Enterprise AI expansion is relevant primarily to workflow administration, result routing, demand forecasting, quality monitoring, and population-level screening analytics rather than replacing validated diagnostic methods. Workflow automation can connect ordering, specimen tracking, result notification, clinical review, and referral processes, reducing manual coordination across fragmented care environments. Vendors that integrate diagnostic devices with secure digital systems can strengthen service value for clinics, laboratories, and public health programs.

Vertical specialization will support differentiated products for antenatal screening, sexual health clinics, community outreach, urgent care, and retail healthcare. Multilingual instructions and result communication improve usability across diverse populations, while accessible customer engagement tools support appropriate next steps after testing. Customer engagement transformation is particularly relevant to home-based testing, where consumers require clear collection instructions, timely results, and access to clinical advice. Commercial opportunities will favor complete test-to-care models supported by validated assays, dependable distribution, privacy safeguards, and partnerships with healthcare providers.

Regional Outlook

XX%Market
Share

XX%Market
Share

XX%Market
Share

XX%Market
Share

XX%Market
Share

Segmentation Analysis

A. Revenue Estimates and Forecast

Market estimates, forecast and CAGR for all the segments covered in the report from 2025 to 2035.

Spacer

B. Market Share Overview

By Technology

Molecular Diagnostics/NAAT

Rapid Immunoassays

Market share of all the segments covered in the report for base year 2025 and forecast year 2035.

Competitive Scenario

A. Company Market Share Analysis

2025

XX%

XX%

XX%

Danaher Corporation

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

Spacer

B. Geographic Revenue

North America

Europe

Asia Pacific

Latin America

Middle East Africa

Spacer

C. Business Segment Revenue

Category 1

Category 2

Category 3

Spacer

D. Company Revenue

Revenue

Regional Analysis

Regional & Country-Level Strategic Insights

North America leads the regional landscape through established diagnostic infrastructure, strong clinical laboratory networks, consumer health channels, and regulatory pathways supporting decentralized testing. The United States anchors commercial activity through molecular point-of-care products and home-based testing authorization. Canada supports demand through public health programs and provincial healthcare procurement, while Mexico offers opportunities through private diagnostic networks and expanding access to decentralized services.

Europe benefits from established national health systems, diagnostic laboratory capacity, and regulatory frameworks for in vitro diagnostic products. Germany, the United Kingdom, and France represent important markets for clinical testing and public health screening. Procurement priorities emphasize evidence, quality assurance, data protection, and alignment with national testing pathways.

Asia Pacific offers substantial long-term opportunity through large populations, expanding healthcare infrastructure, and uneven access to centralized diagnostic facilities. China, India, Japan, South Korea, and Australia represent important country markets. India’s updated STI guidance incorporates laboratory diagnosis and point-of-care approaches, supporting structured testing pathways across public and private healthcare settings.

Latin America is shaped by public health screening, private laboratory expansion, and procurement requirements across Brazil, Argentina, and other countries. Affordability, distribution reach, and dependable supply remain central purchasing considerations.

Middle East & Africa presents opportunities through antenatal screening, HIV and syphilis programs, community testing, and investment in diagnostic access. Gulf healthcare systems prioritize modern diagnostic infrastructure, while African markets place strong emphasis on accessible, quality-assured testing and public health partnerships.

Technology, Innovation & Derivative Trends

Technology development is centered on faster molecular workflows, multiplex detection, simplified specimen preparation, and compact testing devices. Generative AI is relevant to supporting patient communication, translating instructions, summarizing non-diagnostic information, and assisting administrative workflows, but clinical interpretation remains governed by validated assays and qualified healthcare professionals. Multimodal interaction across mobile applications, text, voice, and visual instructions can improve specimen collection guidance and consumer usability. Retrieval-augmented generation can support controlled access to approved instructions, product documentation, and clinical protocols when implemented with appropriate governance.

Conversational analytics can help providers understand service utilization, identify workflow bottlenecks, and improve follow-up processes without exposing sensitive patient information unnecessarily. API interoperability links diagnostic devices with laboratory systems, electronic health records, telehealth platforms, and public health reporting infrastructure. Enterprise orchestration coordinates testing orders, specimen status, results, referrals, and inventory. These capabilities support more connected service delivery, while data security, consent management, and clinical validation remain essential.

Competitive Landscape Overview

Competition combines diversified diagnostics companies, molecular platform manufacturers, rapid-test specialists, and consumer health providers. Established suppliers compete through assay breadth, installed infrastructure, regulatory experience, and distribution relationships. Specialist manufacturers differentiate through compact devices, simplified workflows, home-testing formats, and focused pathogen panels. Pricing structures range from standalone kit sales to instrument-and-consumable arrangements, volume contracts, public procurement tenders, and direct-to-consumer offers.

Integration capability is an important differentiator as healthcare providers seek connections with laboratory information systems, electronic health records, and digital care services. Enterprise partnerships support clinical validation, distribution, product development, and access to new customer groups. Regulatory authorization and reliable clinical evidence remain critical purchasing criteria, particularly for self-testing products. The competitive landscape therefore rewards companies that combine diagnostic performance with accessible deployment, cost control, and effective post-test care pathways.

Key Players in the Rapid STI Testing Market

The competitive field includes established diagnostics companies, rapid-test specialists, and developers of molecular point-of-care platforms. Their portfolios span rapid immunoassays, HIV and syphilis screening, molecular STI panels, self-testing products, and specimen collection solutions. Competitive participation varies by pathogen, geography, regulatory authorization, and testing setting.

• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Visby Medical, Inc.
• SD Biosensor, Inc.
• bioLytical Laboratories Inc.
• Trinity Biotech plc
• Biosynex SA
• OraSure Technologies, Inc.
• NOWDiagnostics, Inc.
• Access Bio, Inc.
• Guangzhou Wondfo Biotech Co., Ltd.
• InTec Products, Inc.
• MedMira Inc.
• AAZ

Recent Developments — Rapid STI Testing Market (2025–2026)

Recent activity reflects regulatory progress, commercial launches, molecular platform development, and investment in decentralized testing. The following developments illustrate product and channel expansion across professional and consumer settings.

• January 2025 — Roche received FDA 510(k) clearance and CLIA waiver for cobas liat STI multiplex assay panels, expanding near-patient molecular testing for chlamydia, gonorrhea, and Mycoplasma genitalium.
• March 2025 — Visby Medical received FDA De Novo authorization for its Women’s Sexual Health Test, enabling over-the-counter home testing for chlamydia, gonorrhea, and trichomoniasis.
• May 2025 — Visby Medical submitted its Men’s Sexual Health Test to the FDA, extending its development pipeline toward rapid molecular testing using male urine samples.
• June 2025 — Linear Diagnostics secured £1 million in NIHR funding to advance development and clinical evaluation of its rapid STI diagnostic platform.
• June 2025 — Visby Medical secured up to USD 65 million in financing to accelerate the commercial launch of its FDA-authorized at-home STI test.
• December 2025 — Visby Medical announced national availability of its at-home PCR STI test through direct-to-consumer partners, extending consumer access and home-delivery options.
• January 2026 — OraSure Technologies announced FDA submissions for its rapid molecular chlamydia and gonorrhea self-test and an at-home urine collection device, advancing its decentralized diagnostics strategy.
• May 2026 — AAZ and En Carta Diagnostics signed a co-development and commercialization agreement for rapid molecular chlamydia and gonorrhea tests for clinical, pharmacy, and home settings.

Methodology & Data Credibility

The study applies bottom-up modeling across test categories, pathogen coverage, sample types, testing settings, end users, and distribution channels. Revenue estimates are developed through product-level assessment, manufacturer disclosures, diagnostic procedure economics, procurement patterns, and regional healthcare expenditure analysis. Triangulation compares supplier-side information with demand-side purchasing evidence, public health testing programs, regulatory databases, and published diagnostic guidance. Executive interviews with manufacturers, laboratory managers, procurement specialists, clinicians, distributors, and public health stakeholders provide commercial context. Demand-side validation examines testing volumes, care pathways, institutional budgets, and adoption barriers, while supply-side validation evaluates product availability, pricing structures, production capacity, and distribution reach. Cross-region verification accounts for differences in reimbursement, regulation, healthcare infrastructure, and testing access. Forecast assumptions are reviewed against product pipelines and commercialization milestones.

Who Should Read This Report

This report is designed for diagnostic manufacturers, molecular testing companies, rapid assay developers, and medical device suppliers evaluating product development and commercialization opportunities. Healthcare providers, hospital networks, sexual health clinics, diagnostic laboratories, and pharmacy operators can use the analysis to assess testing workflows, technology selection, and procurement priorities. Investors, private equity firms, and corporate strategy teams gain insight into competitive positioning, emerging product categories, and commercial expansion pathways. Public health agencies, government procurement bodies, and non-governmental organizations can assess the availability of rapid testing solutions for screening and community programs. Distributors, contract manufacturers, and digital healthcare providers can identify partnership opportunities across specimen collection, test delivery, result communication, and follow-up care.

What This Report Delivers

The report delivers a structured assessment of global rapid STI diagnostics, covering market size, forecast outlook, technology developments, competitive positioning, and regional demand conditions. It evaluates molecular diagnostics and rapid immunoassays, infection-specific testing requirements, single-pathogen and multiplex formats, specimen categories, testing settings, end users, and distribution channels. The analysis examines purchasing behavior, vendor pricing, regulatory requirements, supply-chain considerations, and operational barriers affecting deployment. Company profiling identifies established diagnostic suppliers and specialist developers across professional and consumer testing environments. Recent product authorizations, funding announcements, platform developments, and commercialization initiatives provide context for competitive change. The report supports market entry assessment, product portfolio planning, investment screening, procurement strategy, and regional expansion decisions.

Rapid STI Testing Market Report Segmentation

By Technology

• Molecular Diagnostics/NAAT
• Rapid Immunoassays

By Infection Type

• Chlamydia
• Gonorrhea
• Syphilis
• HIV
• Trichomoniasis
• Genital Herpes
• Mycoplasma genitalium
• Other Sexually Transmitted Infections

By Test Format

• Single-Pathogen Tests
• Multiplex Tests

By Sample Type

• Blood
• Urine
• Genital Swabs
• Oral and Rectal Swabs
• Other Specimen Types

By Testing Setting

• Point-of-Care Testing
• Home-Based Self-Testing
• Decentralized Clinical Testing
• Laboratory-Based Rapid Testing

By End User

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Public Health and Community Organizations
• Pharmacies and Retail Healthcare Providers
• Home Users

By Distribution Channel

• Direct Sales
• Distributors and Medical Suppliers
• Online Channels
• Government and Institutional Procurement

By Region

• North America: United States, Canada, Mexico
• Europe: Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe
• Asia Pacific: China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific
• Latin America: Brazil, Argentina, Rest of Latin America
• Middle East & Africa: Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa